HMD.AU · HeraMED Limited

-

Please sign in to comment on HMD.AU

1 Comment

Admin

4 years, 1 month ago

HeraMED Limited is currently in a long term uptrend where the price is trading 73.5% above its 200 day moving average.

From a valuation standpoint, the stock is 4.7% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 269.6.

HeraMED Limited's total revenue sank by 94.2% to $3K since the same quarter in the previous year.

Its net income has dropped by 13.9% to $-2M since the same quarter in the previous year.

Finally, its free cash flow grew by 7.8% to $-782K since the same quarter in the previous year.

Based on the above factors, HeraMED Limited gets an overall score of 2/5.

Exchange	AU
CurrencyCode	AUD
Sector	Healthcare
Industry	Medical Devices
ISIN	AU0000028367

Market Cap	14M
PE Ratio	None
Target Price	None
Beta	0.34
Dividend Yield	None

ABOUT

HeraMED Limited

HeraMED Limited, a medical data and technology company, develops, manufactures, and sells home-based maternity monitoring technology in Australia and the United States. It also provides HeraBEAT, a medical device for fetal and maternal heart rate used by pregnant women; and HeraCARE, a remote fetal heart rate monitoring solution. The company has a collaboration agreement with Mayo Clinic for the development of its HeraCARE pregnancy management platform; and Broward Health for deployment of its HeraCARE to deliver care outcomes for pregnant mothers. HeraMED Limited was founded in 2011 and is based in Camberwell, Australia.

HMD.AU · HeraMED Limited

-

HeraMED Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest HeraMED Limited using a moving average strategy